Skip to content
Screener

McKesson MCK Prescription Technology Solutions — Total revenues

Other segment segments

North American Pharmaceutical
$86.77B—
Oncology & Multispecialty
$14.22B—
Medical-Surgical Solutions
$2.82B+4.4%

Similar metrics at other companies

Phreesia logo
PHRTechnology Solutions Segment — Total revenues
$130.94M+12.9%
Ziff Davis logo
ZDTechnology & Shopping — Total revenues
$71.16M-12.9%
Nasdaq, Inc. logo
NDAQFinancial Technology — Total revenues
$539M+16.2%
The Baldwin Insurance Group, Inc. logo
BWINUnderwriting, Capacity & Technology Solutions — Total revenues
$134.94M+7.8%
Intercontinental Exchange logo
ICETechnology Service — Total revenues
$645M+8.0%
Intercontinental Exchange logo
ICEMortgage Technology — Total revenues
$557M+4.9%

Other financials

Income statement

See full
Revenue$105.38B+7.7%
Gross profit$3.7B+12.4%
Operating income$1.3B+27.3%
Net income$614.0M-21.7%
EPS (diluted)$5.15-17.6%

Balance sheet

See full
Cash & equivalents$5.3B+95.9%
Total debt$13.0B+15.7%
Total equity-$4.2B-116%
Total assets$88.3B+8.6%

Cash flow

See full
Operating cash flow-$220.0M+76.0%
CapEx$112.0M+0.9%
Free cash flow-$332.0M+67.7%

Valuation

See full
Market cap$102.7B+16.8%
Enterprise value$110.42B+14.5%
P/E22.4×-5.4×
P/S0.3×0.0×

Profitability

See full
Gross margin3.6%+0.1pp
Operating margin1.6%+0.4pp
Net margin1.1%+0.3pp
FCF margin1.6%0.0pp

Returns & leverage

See full
Return on equity36%—
Debt / equity2×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: McKesson’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:29 PM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000927653-26-000234
(In millions)Three Months Ended June 30, 2026Three Months Ended June 30, 2025
Segment revenues (1)
North American Pharmaceutical$86,773$82,729
Oncology & Multispecialty14,22210,658
Prescription Technology Solutions1,5661,434
Medical-Surgical Solutions2,8192,701
Other—305
Total revenues$105,380$97,827
Other segment expense, net (2)

Item 1. Condensed Consolidated Financial Statements.

FAQ

What is McKesson's prescription technology solutions — total revenues?
McKesson (MCK) reported prescription technology solutions — total revenues of $1.57B in Q2 2026.
How has McKesson's prescription technology solutions — total revenues changed year-over-year?
McKesson's prescription technology solutions — total revenues increased by 9.2% year-over-year, from $1.43B to $1.57B.
What is the long-term trend for McKesson's prescription technology solutions — total revenues?
Over 4 years (2022 to 2026), McKesson's prescription technology solutions — total revenues has grown at a 10.7% compound annual growth rate (CAGR), from $3.86B to $5.81B.
What does prescription technology solutions — total revenues mean?
This metric represents the total gross revenue generated by the Prescription Technology Solutions segment from its services and technology offerings. It is a primary indicator of the segment's market demand and growth trajectory. It excludes inter-segment eliminations to show the standalone contribution of the technology business.

Ask your AI about McKesson's prescription technology solutions — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude